Novavax Inc
NVAX6.800USD
+0.240+3.66%
交易中 （美東）報價延遲15分鐘
1.10B總市值
2.30本益比TTM
關於 Novavax Inc 公司
Novavax, Inc. 是一家生物技術公司，致力於發現、開發和商業化用於預防嚴重傳染病的疫苗。該公司提供差異化疫苗平臺，該平臺結合了重組蛋白方法、先進的納米顆粒技術和其專利的 Matrix-M 佐劑來增強免疫反應。該公司有一個用於預防 COVID-19 的疫苗商業計劃，其中包括 Nuvaxovid 原型 COVID-19 疫苗（NVX-CoV2373 或原型疫苗）和 Nuvaxovid 更新的 COVID-19 疫苗（NVX-CoV2601 或更新疫苗）（統稱 COVID-19 疫苗）。該公司正在推進其他候選疫苗的開發，包括其 COVID19-流感聯合 (CIC) 候選疫苗和其他候選疫苗。其 COVID-19 疫苗和其他候選疫苗結合了該公司專有的 Matrix-M 佐劑，以增強免疫反應並刺激更高水平的功能性抗體並誘導細胞免疫反應。
公司簡介
公司代碼NVAX
公司名稱Novavax Inc
上市日期May 16, 1973
CEOMr. John C. Jacobs
員工數量952
證券類型Ordinary Share
年結日May 16
公司地址700 Quince Orchard Road
城市GAITHERSBURG
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編20878
電話12402682000
網址https://www.novavax.com/?locale=US
公司代碼NVAX
上市日期May 16, 1973
CEOMr. John C. Jacobs
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. John C. Jacobs
Mr. John C. Jacobs
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
136.73K
--
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Independent Director
Independent Director
71.31K
+17.11%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Independent Director
Independent Director
64.76K
+19.18%
Ms. Elaine O'hara
Ms. Elaine O'hara
Executive Vice President, Chief Strategy Officer
Executive Vice President, Chief Strategy Officer
57.48K
--
Ms. Margaret G. (Margie) Mcglynn
Ms. Margaret G. (Margie) Mcglynn
Independent Chairman of the Board
Independent Chairman of the Board
36.01K
+40.72%
Ms. Rachel K. King
Ms. Rachel K. King
Independent Director
Independent Director
35.61K
+41.37%
Mr. Richard J. (Rick) Rodgers
Mr. Richard J. (Rick) Rodgers
Independent Director
Independent Director
35.11K
+42.20%
Mr. Mark J. Casey
Mr. Mark J. Casey
Executive Vice President, Chief Legal Officer, Company Secretary
Executive Vice President, Chief Legal Officer, Company Secretary
31.97K
--
Mr. James Patrick (Jim) Kelly
Mr. James Patrick (Jim) Kelly
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
--
--
Dr. Robert Walker, M.D.
Dr. Robert Walker, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. John C. Jacobs
Mr. John C. Jacobs
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
136.73K
--
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Independent Director
Independent Director
71.31K
+17.11%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Independent Director
Independent Director
64.76K
+19.18%
Ms. Elaine O'hara
Ms. Elaine O'hara
Executive Vice President, Chief Strategy Officer
Executive Vice President, Chief Strategy Officer
57.48K
--
Ms. Margaret G. (Margie) Mcglynn
Ms. Margaret G. (Margie) Mcglynn
Independent Chairman of the Board
Independent Chairman of the Board
36.01K
+40.72%
Ms. Rachel K. King
Ms. Rachel K. King
Independent Director
Independent Director
35.61K
+41.37%
收入明細
單位: USD更新時間: 7月6日 週日
單位: USD更新時間: 7月6日 週日
FY2025Q1
暫無數據
地區USD
名稱
營收
佔比
Canada
575.67M
86.38%
Rest of the world
43.29M
6.50%
United States
39.41M
5.91%
Europe
8.09M
1.21%
業務
地區
暫無數據
股東統計
更新時間: 6月4日 週三
更新時間: 6月4日 週三
持股股東
股東類型
持股股東
持股股東
佔比
The Vanguard Group, Inc.
9.66%
BlackRock Institutional Trust Company, N.A.
7.14%
Shah Capital Management, Inc.
7.11%
State Street Global Advisors (US)
4.35%
Sanofi SA
4.25%
Other
67.50%
持股股東
持股股東
佔比
The Vanguard Group, Inc.
9.66%
BlackRock Institutional Trust Company, N.A.
7.14%
Shah Capital Management, Inc.
7.11%
State Street Global Advisors (US)
4.35%
Sanofi SA
4.25%
Other
67.50%
股東類型
持股股東
佔比
Investment Advisor
22.62%
Investment Advisor/Hedge Fund
18.46%
Hedge Fund
10.75%
Corporation
8.26%
Research Firm
4.80%
Pension Fund
0.81%
Individual Investor
0.52%
Bank and Trust
0.43%
Venture Capital
0.04%
Other
33.30%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
550
108.02M
66.69%
-12.99M
2025Q1
575
113.82M
70.29%
-16.33M
2024Q4
593
111.51M
69.72%
-5.93M
2024Q3
597
103.31M
64.96%
-4.25M
2024Q2
652
92.80M
65.79%
-10.97M
2024Q1
753
86.51M
64.06%
-11.91M
2023Q4
848
86.68M
74.23%
+6.21M
2023Q3
919
70.31M
60.51%
-6.00M
2023Q2
957
58.87M
62.55%
-19.22M
2023Q1
1015
61.08M
70.93%
-3.17M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
The Vanguard Group, Inc.
15.64M
9.66%
-57.51K
-0.37%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
11.56M
7.14%
-518.90K
-4.30%
Mar 31, 2025
Shah Capital Management, Inc.
11.13M
6.87%
-17.00K
-0.15%
Mar 31, 2025
State Street Global Advisors (US)
7.04M
4.35%
-662.21K
-8.60%
Mar 31, 2025
Sanofi SA
6.88M
4.25%
--
--
Mar 31, 2025
SK Bioscience Co., Ltd.
6.50M
4.01%
--
--
May 10, 2024
Coatue Management, L.L.C.
3.84M
2.37%
+3.84M
--
Mar 31, 2025
Geode Capital Management, L.L.C.
3.76M
2.32%
+106.31K
+2.91%
Mar 31, 2025
D. E. Shaw & Co., L.P.
3.26M
2.01%
-2.53M
-43.68%
Mar 31, 2025
Park West Asset Management LLC
2.53M
1.56%
+2.53M
--
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
ProShares Nanotechnology ETF
2.42%
iShares Genomics Immunology and Healthcare ETF
2.14%
Virtus LifeSci Biotech Products ETF
1.7%
ALPS Medical Breakthroughs ETF
0.69%
SPDR S&P Biotech ETF
0.41%
Direxion Daily S&P Biotech Bull 3X Shares
0.23%
Invesco Nasdaq Biotechnology ETF
0.11%
First Trust Small Cap Growth AlphaDEX Fund
0.11%
ProShares Ultra Nasdaq Biotechnology
0.11%
iShares Biotechnology ETF
0.1%
查看更多
ProShares Nanotechnology ETF
佔比2.42%
iShares Genomics Immunology and Healthcare ETF
佔比2.14%
Virtus LifeSci Biotech Products ETF
佔比1.7%
ALPS Medical Breakthroughs ETF
佔比0.69%
SPDR S&P Biotech ETF
佔比0.41%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.23%
Invesco Nasdaq Biotechnology ETF
佔比0.11%
First Trust Small Cap Growth AlphaDEX Fund
佔比0.11%
ProShares Ultra Nasdaq Biotechnology
佔比0.11%
iShares Biotechnology ETF
佔比0.1%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
